* BioLife Solutions Inc BLFS.OQ BLFS.O is expected
to show a
fall in quarterly revenue when it reports results on May 9 for
the period ending March 31 2024
* The Bothell Washington-based company is expected to
report a
31.0% decrease in revenue to $26.007 million from $37.7 million
a year ago, according to the mean estimate from 8 analysts,
based on LSEG data.
* LSEG's mean analyst estimate for BioLife Solutions Inc is
for a
loss of 28 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for BioLife
Solutions
Inc is $21.50, above its last closing price of $18.60.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Dec. 31 2023 -0.35 -0.34 -0.30 Beat 12.2
Sep. 30 2023 -0.38 -0.37 -0.30 Beat 20
Jun. 30 2023 -0.21 -0.20 -0.23 Missed -15
Mar. 31 2023 -0.22 -0.21 -0.32 Missed -51.3
Dec. -0.20 -0.17 -1.15 Missed -590
31 2022
Sep. 30 2022 -0.18 -0.17 -0.23 Missed -35.3
Jan. 1 0001 -0.23 -0.21 -0.06 Beat 72
Mar. 31 2022 -0.25 -0.25 -0.17 Beat 31.1
This summary was machine generated May 8 at 02:24 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)